# Healthcare Podcast Weekly Digest: May 23–29, 2026

> Healthcare podcast digest for May 23–29, 2026. Eli Lilly's retatrutide blowout and a triple vaccine roll-up, the ASCO 2026 plenary setup (Revolution Medicines pan-RAS and Summit/Akeso ivonescimab), UnitedHealth's Medicare Advantage rerate, and FDA leadership upheaval.


## Healthcare Podcast Weekly Digest

### Week of May 23–29, 2026

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 1. Opening Summary

This week's healthcare tape was dominated by two stories: **Eli Lilly's blowout retatrutide Phase 3 readout** (up to 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, "a new bar for next-generation therapies" per Wolfe Research) and the **ASCO 2026 pre-conference setup**, where Revolution Medicines' pan-RAS inhibitor (Daraxin Rassib, reportedly doubling OS to ~13.2 months in 2L pancreatic) and Summit/Akeso's ivonescimab (PD-1/VEGF bispecific vs. Keytruda+chemo in 1L NSCLC) are queued as plenary readouts. Managed care had its strongest tape in months, with UNH price targets lifted by Mizuho, UBS, Barclays, Bernstein, and Oppenheimer on signs Medicare Advantage margin recovery is real, while a Section 232 100% tariff proclamation on imported APIs/finished drugs (effective July 31, 2026) is forcing a structural reshoring response from non-MFN-signatory pharma.

---

## 2. Key People This Week

| Speaker | Affiliation | Key Quote |
| --- | --- | --- |
| **Chris Liu** | Senior Research Analyst, RTW Investments LP | *"If you're a pancreatic cancer patient... With Revolution Medicine's new drug, you have doubled the chances of being alive, and you're taking an oral pill."* ([The RTW Podcast, May 28, 2026](https://app.matterfact.com/podcasts)) |
| **Jeremy Levin** | Founder/Chairman, Ovid Therapeutics; fmr. CEO Teva | *"Predictability at the FDA is not bureaucracy. It's fundamental infrastructure... That is being shaken."* ([The Readout Loud, May 28, 2026](https://app.matterfact.com/podcasts)) |
| **Adam Forrestine** | Reporter, STAT | On Verve-102: *"The 62% reduction... is great. But that's also a cholesterol reduction that is already achieved by statins and other medicines already available to physicians."* ([The Readout Loud, May 28, 2026](https://app.matterfact.com/podcasts)) |
| **Sandro Holzer** | CSO, Newland Laboratories | *"The GLP-1 wave has singularly consumed [peptide CDMO] capacity globally."* ([Off Script, May 26, 2026](https://app.matterfact.com/podcasts)) |
| **Alasdair Milton** | Principal, KPMG | *"I just know there's great science that never sees the light of day because it's killed in a quarterly portfolio review."* ([Beginner's Mind, May 25, 2026](https://app.matterfact.com/podcasts)) |
| **Daniel Skovronsky** | CSO & President LRL, Eli Lilly | *"These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences."* (LLY press release on $3.83B vaccine M&A, May 26, 2026) |
| **Kenneth Custer** | EVP & President Cardiometabolic Health, Eli Lilly | *"No two patients with obesity or diabetes are alike, and their needs evolve over time. That's exactly why choice matters."* (LLY ADA preview, May 28, 2026) |
| **Neil McFarlane** | CEO, Zevra Therapeutics | On FDA: *"The consistency on how those rules are applied is probably one of the biggest challenges that we see as a manufacturer."* ([Business of Biotech, May 25, 2026](https://app.matterfact.com/podcasts)) |

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 3. Hot Topics

### Eli Lilly (LLY): Three discrete catalysts, all positive

- **Retatrutide TRIUMPH-1 (May 21):** Triple-agonist (GIP/GLP-1/glucagon) Phase 3 hit primary endpoint at all doses. **12 mg: 70.3 lbs lost / 28.3% body weight at 80 weeks; 85 lbs / 30.3% at 104 weeks** in BMI ≥35 extension cohort. 45.3% of 12 mg patients hit ≥30% weight loss (bariatric-surgery range). RBC modeling 2030 sales of **$4.9B** and 2034 sales of **$11.0B** at 70% PoS; Wolfe sees it setting a "new bar for next-generation therapies."
- **Verve-102 Heart-2 (May 25):** Single IV dose of in vivo base-editing therapy produced dose-dependent PCSK9 reductions of **51%–88%** and LDL-C reductions of **9%–62%**, durable up to 18 months. Phase 2 start expected by year-end. STAT analysts skeptical of differentiation vs. statins/PCSK9 mAbs.
- **Vaccine roll-up (May 26):** LLY acquiring Curevo (~$1.5B, amezosvatein shingles vaccine), LimmaTech (~$780M, S. aureus), and Vaccine Company (~$1.55B, EBV), **~$3.83B combined** in cash + milestones. Strategic pivot into infectious disease prevention.
- **PBM coverage win (May 28):** All three largest PBMs will cover LLY's full obesity portfolio. CVS Caremark Commercial template starts June 1 for Foundayo; $25/month commercial copay; $50/month Medicare via the new GLP-1 Bridge.
- **Engage Biologics tuck-in (May 20):** Up to $202M cash for non-viral DNA delivery platform (Tethosome).
- **BofA raised PT to $1,251 (from $1,133); Wolfe to $1,350; Jefferies to $1,330.**

### UnitedHealth (UNH): Sell-side capitulating to MA recovery

Five PT raises in eight days:

| Firm | New PT | Prior | Rating |
| --- | --- | --- | --- |
| Bernstein (May 27) | $492 | $444 | Outperform |
| UBS (May 22) | $460 | $410 | Buy |
| Mizuho (May 20) | $440 | $410 | Outperform |
| Barclays (May 26) | $429 | $373 | Overweight |
| Oppenheimer (May 27) | $420 | $405 | Outperform |

UBS notes the cohort: *"Managed care organizations broadly raised guidance after stronger-than-expected Q1 results benefited from favorable respiratory trends and seasonal cost patterns, while improved Medicare Advantage rates, steadier ACA exchange enrollment, and modest Medicaid outperformance have boosted confidence in margin recovery."* Bernstein cites a **16% adjusted EPS CAGR** in the cyclical recovery phase as multiple-justifying.

### Revolution Medicines (RVMD): ASCO plenary headline

**Daraxin Rassib pan-RAS inhibitor:** Phase 3 in 2L pancreatic cancer reportedly hit ~**13.2 month mOS vs. ~6.7 month SoC** (roughly doubling). Plenary at ASCO on Sunday (~May 31). RTW's Chris Liu sees it as *"first validation of this entire class"*; RAS mutations span ~30% of tumors (pancreatic largest; colon 40–50%; NSCLC ~25%). Frontline Phase 3 is enrolling.

### Summit Therapeutics / Akeso (SMMT): Ivonescimab plenary slot

PD-1/VEGF bispecific Phase 3 in 1L NSCLC vs. Keytruda+chemo presents at ASCO immediately before RVMD. RTW's Liu: *"If that trial shows super positive result, we can imagine that will ungate a big wave of next-gen immunotherapy across multiple tumor types."* STAT's Forrestine is more guarded on global translation of China-origin data.

### GLP-1 oncology read-through

The Wall Street Journal (May 22): observational data suggests **Ozempic/Mounjaro users had ~50% lower lung and breast cancer progression and were 25% less likely to be diagnosed with breast cancer**. ASCO Abstract 3143 (per web research) shows **38%–50% reduction in metastatic progression** of obesity-related cancers vs. DPP-4 inhibitors, and **33% lower overall mortality** with high tumor GLP-1 receptor expression. Materially expands the GLP-1 TAM narrative.

---

## 4. Key Debates

### Debate 1: Verve-102, paradigm shift or hype?

- **Bull:** Single infusion, durable 18-month effect, "one-and-done" cardiovascular prevention; 62% LDL drop at top dose; LLY balance sheet to fund development.
- **Bear (Forrestine, DeAngelis on [The Readout Loud, May 28](https://app.matterfact.com/podcasts)):** Statins and PCSK9 mAbs already deliver this magnitude of LDL reduction. Forrestine: *"The drug went viral... it tapped into the longevity folks."* Phase 1 cohort small; familial hypercholesterolemia population, not general; reimbursement path unclear.

### Debate 2: Can China-origin clinical data translate globally?

- **Bull (Chris Liu, RTW, [May 28](https://app.matterfact.com/podcasts)):** *"China is not only catching up to the rest of the world, it's almost kind of leading the speed of drug development nowadays."* Ivonescimab is the test case; positive plenary opens the floodgates.
- **Bear (Forrestine, STAT, [May 28](https://app.matterfact.com/podcasts)):** *"To date, we haven't seen global studies... that have replicated those results. Yes, those studies are being conducted... In some cases, they may not."*

### Debate 3: FDA disruption, existential or transitional?

- **Bear (Levin, Ovid, [May 28](https://app.matterfact.com/podcasts)):** Makary resigned ~May 23; Diamantis acting commissioner; *"90% of the top leadership has been either removed or has gone. When DOGE entered, they cut 20% straight out without even knowing what they were cutting."* The titans are *"dead silent."*
- **Measured (McFarlane, Zevra, [May 25](https://app.matterfact.com/podcasts)):** Frameworks have *"sufficient flexibility"* but consistency of application is the real problem.

### Debate 4: GLP-1 capital allocation, pile in or rotate?

- **Crowded-trade bear (Levin, [May 28](https://app.matterfact.com/podcasts)):** *"Bold doesn't mean reckless... It means choosing important science, not fashionable science, not another GLP-1, not another PD-1."*
- **Bull (LLY data + PBM + Medicare Bridge):** Retatrutide is best-in-class; PBM and Medicare access removing reimbursement overhang; oncology read-through expanding TAM.

### Debate 5: Managed care, durable rerate or relief rally?

- **Bull (Barclays, [May 26](https://app.matterfact.com/podcasts)):** Post-Q1 moves "durable"; prefers managed care over facilities given inflation and commercial mix risks to providers.
- **Bear (implicit):** Specialty drug cost pressure, GLP-1 utilization, and behavioral health remain structural margin headwinds (per UBS, May 22).

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 5. Emerging Themes

1. **GLP-1 as oncology adjunct.** ASCO Abstract 3143 read-through, combined with the WSJ tumor-progression data, converts obesity drugs into a cardiometabolic + oncology platform. Watch for sell-side TAM revisions.
2. **Vaccine M&A as the "next pharma platform."** LLY's $3.83B three-deal sweep (Curevo/LimmaTech/Vaccine Co.) follows the Skovronsky thesis that prevention is more durable than treatment. Watch peers (MRK, GSK, PFE) for response.
3. **In vivo gene editing leaves the lab.** Verve-102's 18-month durable PCSK9 silencing is the first commercial-grade in vivo base-editing readout. RTW's Liu expects *"dramatic therapeutic effect in solid tumor in two to three years"* from CAR-T progression.
4. **Peptide CDMO capacity as the GLP-1 bottleneck.** Holzer (Newland) frames 18–24 more months of capacity tightness through ~late 2027, read-through to BACH, Polypeptide, Catalent, and other peptide CDMOs.
5. **Reshoring as a non-MFN-signatory survival strategy.** Section 232 100% tariffs on imported APIs/finished drugs (effective July 31) create a bifurcation: MFN-signers (the 17 named majors) get 0% through early 2029, others must secure approved onshoring plans for a 20% rate.
6. **Pan-RAS as the next big oncology class.** If RVMD's ASCO plenary holds, the RAS-mutant footprint (pancreatic + colon + NSCLC) is the largest tumor-agnostic opportunity since checkpoint inhibitors.

---

## 6. Deals & M&A Tracker

| Buyer | Target | Value | Asset / Rationale | Date |
| --- | --- | --- | --- | --- |
| Eli Lilly | Curevo | Up to **$1.50B** cash | Amezosvatein, next-gen shingles vaccine | May 26 |
| Eli Lilly | LimmaTech Biologics | Up to **$780M** cash | LTB-SA7 S. aureus vaccine; bacterial pathogens | May 26 |
| Eli Lilly | Vaccine Company | Up to **$1.55B** cash | In vivo nanoparticle EBV vaccine | May 26 |
| Eli Lilly | Engage Biologics | Up to **$202M** cash | Tethosome non-viral DNA delivery platform | May 20 |
| Curium (rumored) | Lantheus (LNTH) | ~**$7B** (talks, unverified) | Radiopharma platform consolidation per [Telltales, May 23](https://app.matterfact.com/podcasts) | May 23 |
| Merck KGaA | Springworks (ex-PFE spin) | ~**$4B** exit (closed early 2026) | Cited as PFE externalization success per [Beginner's Mind, May 25](https://app.matterfact.com/podcasts) | Cited May 25 |

LLY's vaccine triple-deal is the headline transaction of the week, combined ~$3.83B announced May 26, with Skovronsky framing it as a pivot from treatment to prevention.

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 7. Regulatory Watch

### FDA Leadership

- **Marty Makary resigned (~May 23, 2026)**; Kyle Diamantis is acting commissioner ([The Readout Loud, May 28](https://app.matterfact.com/podcasts)). Per Levin, *"90% of the top leadership has been either removed or has gone"* over the past year; DOGE cut ~20% of FDA headcount.

### Trade / Tariffs

- **Section 232 100% tariffs on imported APIs and finished drugs take effect July 31, 2026.** MFN-signatory manufacturers (final of 17 capitulated late April) get 0% through early 2029; others must secure approved domestic onshoring plans to qualify for a 20% rate.
- **EU-Mercosur Interim Trade Agreement** provisionally took effect May 1, 2026, phasing out medical device tariffs up to 16% in South America (tailwind for EU medtech OEMs).

### IRA / Medicare

- **IRA Maximum Fair Prices (≥38% discounts)** for the first 10 Part D drugs are live for plan year 2026.
- **Medicare Part D OOP cap of $2,100** for 2026 (deductible $615); plan sponsors shifting toward co-insurance over flat copays on lower specialty tiers.
- **Medicare GLP-1 Bridge program launches July 2026**, Part D enrollees get Wegovy/Zepbound for **$50/month flat copay**. Material near-term inflection for senior GLP-1 utilization, per LLY's May 28 disclosure that Medicare Part D beneficiaries are eligible starting July 1.

### Approvals & PDUFA dates

- **Lantheus 2501 PDUFA: June 29, 2026** ([Telltales, May 23](https://app.matterfact.com/podcasts)).
- **Gilead Hepcludex (bulevirtide gmod)**, accelerated FDA approval for chronic Hepatitis D, overcoming earlier CRLs.
- **AbbVie Decnupaz (pivekimab sunirine-pvzy)**, CD123-directed ADC approved; 69.7% CR rate in treatment-naive BPDCN.
- **EMA recommended extending Wegovy authorization** to a daily oral formulation.
- **AD109 (oral combo aroxybutynin + atomoxetine for OSA)**, Phase 3 SynAIRgy positive; FDA fast track; potential 2027 disruption to CPAP medtech.

---

## 8. Week Ahead

### ASCO Annual Meeting (Chicago, May 29 – June 2)

- **Sunday May 31 plenary:** Revolution Medicines (RVMD) Daraxin Rassib Phase 3 in 2L pancreatic, watch for confirmed OS magnitude vs. SoC.
- **Sunday May 31 plenary (preceding RVMD):** Summit/Akeso (SMMT) ivonescimab Phase 3 vs. Keytruda+chemo in 1L NSCLC.
- **Citizens biotech KOL dinner (May 29):** Breast cancer focus, CELC, RLAY, ARVN, ZYME, GILD, LLY, PFE, AZN, NVS.

### American Diabetes Association 86th Scientific Sessions (New Orleans, June 5 – 8)

- Lilly will present new data across Foundayo (orforglipron), Mounjaro, and retatrutide. **LLY investor event Saturday June 6 at 6:00 PM CDT.**

### Key catalysts to track

- **LNTH PDUFA: June 29, 2026** (LNTH 2501).
- **Medicare GLP-1 Bridge launches July 1, 2026**, first wave of subsidized GLP-1 access for Part D beneficiaries.
- **CVS Caremark commercial coverage of LLY's Foundayo: starts June 1** (broadens by Oct 1).
- **Section 232 pharma tariff effective date: July 31, 2026**, last window for non-MFN signatories to secure onshoring exemptions.
- **Retro Biosciences (private)**, initial Alzheimer's data expected ~August 2026.

---

### Coverage gaps to flag

This week's podcast coverage skewed heavily to oncology (ASCO setup) and biotech systemic issues. No material discussion of Humana, Elevance, CVS Health (operational), HCA Healthcare, Intuitive Surgical, Medtronic, Boston Scientific, Stryker, Dexcom, Thermo Fisher, Danaher, Moderna, Vertex, Gilead, J&J, AbbVie, or Amgen. UNH coverage in this digest is news-flow / sell-side action only, no podcast color.

---

## Sources

- [The RTW Podcast, May 28, 2026](https://app.matterfact.com/podcasts)
- [The Readout Loud, May 28, 2026](https://app.matterfact.com/podcasts)
- [Off Script, May 26, 2026](https://app.matterfact.com/podcasts)
- [Beginner's Mind, May 25, 2026](https://app.matterfact.com/podcasts)
- [Business of Biotech, May 25, 2026](https://app.matterfact.com/podcasts)
- [Telltales, May 23, 2026](https://app.matterfact.com/podcasts)

*Sources: research compiled from podcast transcripts, news flow (TheFly, MT Newswires) for UNH and LLY, and open-web context on tariffs/IRA/ASCO read-throughs. Inline links route to source episodes where applicable.*

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```